Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | EIF4E | P06730 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TOP1 | P11387 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12879159 | 1.00 | PNP (0.71) | PNPLMNASMN1; SMN2ADORA1ALDH1A1 | |
| SCHEMBL12892516 | 1.00 | PNP (0.71) | PNPLMNASMN1; SMN2ADORA1ALDH1A1 | |
| SCHEMBL10428124 | 0.88 | PNP (0.68) | PNPLMNASMN1; SMN2ADORA1ALDH1A1 | |
| SCHEMBL12879160 | 0.85 | PNP (0.61) | PNPLMNASMN1; SMN2ADORA1ALDH1A1 | |
| SCHEMBL12879134 | 0.85 | PNP (0.61) | PNPLMNASMN1; SMN2ADORA1ALDH1A1 | |
| SCHEMBL13352079 | 0.85 | PNP (0.71) | PNPLMNASMN1; SMN2ADORA1ALDH1A1 | |
| SCHEMBL27568954 | 0.85 | LMNA (0.71) | PNPLMNASMN1; SMN2ADORA1ALDH1A1 | |
| SCHEMBL2841654 | 0.85 | LMNA (0.71) | PNPLMNASMN1; SMN2ADORA1ALDH1A1 | |
| SCHEMBL13320531 | 0.85 | PNP (0.71) | PNPLMNASMN1; SMN2ADORA1ALDH1A1 | |
| SCHEMBL27568953 | 0.85 | LMNA (0.71) | PNPLMNASMN1; SMN2ADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118586790-B | Scientific and technical element-transformation-structure multidimensional coupling calculation method | 南京大学 | 2024-11-19 | — | — | CN | claimed |
| CN-118675725-A | Family member remote accompanying interaction system based on intensive care unit management information | 浙江大学医学院附属邵逸夫医院 | 2024-09-20 | — | — | CN | claimed |
| CN-118586790-A | Scientific and technical element-transformation-structure multidimensional coupling calculation method | 南京大学 | 2024-09-03 | — | — | CN | claimed |
| EP-4261831-A1 | PREDICTION OF CHEMICAL COMPOUNDS WITH DESIRED PROPERTIES | Bayer AG (DE) | 2023-10-18 | — | — | EP | claimed |
| CN-116482687-B | Amplitude-variable target ISAR imaging translational compensation method based on minimum mean square error | 中国科学院空天信息创新研究院 | 2023-08-15 | — | — | CN | claimed |
| CN-116482687-A | Amplitude-variable target ISAR imaging translational compensation method based on minimum mean square error | 中国科学院空天信息创新研究院 | 2023-07-25 | — | — | CN | claimed |
| CN-112492553-B | Non-orthogonal access method for MTC user clustering in NB-IoT system | 国网江苏省电力工程咨询有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-115291546-A | Control system of intelligent electric power instrument | 帝森克罗德集团有限公司 | 2022-11-04 | — | — | CN | claimed |
| US-4925930-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1990-05-15 | — | — | US | claimed |
| WO-2025261579-A1 | NETWORK NODE, USER EQUIPMENT, AND METHODS PERFORMED THEREIN | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2025-12-26 | — | — | WO | disclosed |
| CN-118586790-B | Scientific and technical element-transformation-structure multidimensional coupling calculation method | 南京大学 | 2024-11-19 | — | — | CN | disclosed |
| US-12103216-B2 | Fluidic systems, devices and methods for inducing anisotropy in polymeric materials | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2024-10-01 | — | — | US | disclosed |
| CN-118675725-A | Family member remote accompanying interaction system based on intensive care unit management information | 浙江大学医学院附属邵逸夫医院 | 2024-09-20 | — | — | CN | disclosed |
| CN-118634747-A | Preparation method of self-reporting and self-repairing composite material | 重庆大学 | 2024-09-13 | — | — | CN | disclosed |
| US-20140288295-A1 | OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES | NEKTAR THERAPEUTICS | 2014-09-25 | — | — | US | disclosed |
| US-8778898-B2 | Oligomer conjugates of heteropentacyclic nucleosides | NEKTAR THERAPEUTICS (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130261072-A1 | OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES | NEKTAR THERAPEUTICS (US) | 2013-10-03 | — | — | US | disclosed |
| US-8466276-B2 | Oligomer conjugates of heteropentacyclic nucleosides | NEKTAR THERAPEUTICS (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110039797-A1 | Oligomer Conjugates of Heteropentacyclic Nucleosides | Nektar Therapetics (US) | 2011-02-17 | — | — | US | disclosed |
| US-4925930-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1990-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039797-A1 | Oligomer Conjugates of Heteropentacyclic Nucleosides | SLC29A2, SLC29A1, GNE | PNP 137/4885LMNA 3873/4885SMN1; SMN2 2799/4885 |
| US-20140288295-A1 | OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES | SLC29A2, SLC29A1, GNE | PNP 137/4885LMNA 3873/4885SMN1; SMN2 2799/4885 |
| US-20130261072-A1 | OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES | GNE, SLC29A2, ABCG2 | PNP 152/4885LMNA 3345/4885SMN1; SMN2 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.